Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice

Immunology Letters

Volumn 162, Issue 1, 2015, Pages 140-148

  Chen, Hui ^a   Gao, Na ^a   Wu, Jiangman ^a   Zheng, Xiaoyan ^a   Li, Jieqiong ^a   Fan, Dongying ^a   An, Jing ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

Dengue virus; DNA vaccine; Flaviviridae virus; Granulocyte macrophage colony stimulating factor; Hepatitis C virus

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 1; DENGUE VIRUS 2; DRUG EFFICACY; FEMALE; FLAVIVIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; MOUSE; NONHUMAN; PLASMID; VACCINATION; VIRUS CORE; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; DISEASE MODEL; FLAVIVIRUS INFECTIONS; GENETICS; HEPACIVIRUS; IMMUNIZATION; IMMUNOLOGY; IMMUNOMODULATION; MORTALITY; SERODIAGNOSIS; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPACIVIRUS; HUMANS; IMMUNIZATION; IMMUNOMODULATION; MICE; NEUTRALIZATION TESTS; PLASMIDS; VACCINES, DNA; VIRAL VACCINES;

EID: 84908396674     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.08.005     Document Type: Article

References (50)

1. Normile D. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013, 342:415.
2. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., Hunsperger E., Kroeger A., Margolis H.S., Martinez E., Nathan M.B., Pelegrino J.L., Simmons C., Yoksan S., Peeling R.W. Dengue: a continuing global threat. Nature Rev Microbiol 2010, 8:S7-S16.
3. Putnak R., Porter K., Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res 2003, 61:445-468.
4. Bray M., Lai C-J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 1991, 185:505-508.
5. Bharati K., Rani R., Vrati S. Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [Macaca mulatta]. Vaccine 2009, 27:10-16.
6. Zhao Z., Wakita T., Yasui K. Inoculation of plasmids-encoding Japanese encephalitis virus prM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice. J Virol 2003, 77:4248-4260.
7. Konishi E., Ajiro N., Nukuzuma C., Masonb P.W., Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 2003, 21:3675-3683.
8. Mellado-Sánchez G., García-Cordero J., Luria-Pérez R., Lázaro-Olan L., Santos-Argumedo L., Gutiérrez-Castañeda B., Estrada-García I., Cedillo-Barrón L. DNA priming E and NS1 constructs-homologous proteins boosting immunization strategy to improve immune response against dengue in mice. Viral immunol 2005, 18:709-721.
9. Kaufman H.L., Flanagan K., Lee C.S.D., Perretta D.J., Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002, 20:1862-1869.
10. Chakrabarti R., Chang Y., Song K., Prud'homme G.J. Plasmids encoding membrane-bound IL-4 or IL-12 strongly co-stimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 2004, 22:1199-1205.
11. Abaitua F., Rodríguez J.R., Garzóna A., Rodrígueza D., Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006, 116:11-20.
12. Nimal S., Heath A.W., Thomas M.S. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 2006, 24:3298-3308.
13. Follador I., Araujo C., Orge G., Cheng L.H., Carvalho L.P.D., Bacellar O., Almeida R.P., Carvalho E.M. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 2002, 20:1365-1368.
14. Chakrabarti R., Zhou Z.F., Chang Y., Prud'homme G.J. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity. Vaccine 2005, 23:4553-4564.
15. Zhang X., Divangahi M., Ngai P., Santosuosso M., Millar J., Zganiacz A., Wang J., Bramson J., Xing Z. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 2007, 25:1342-1352.
16. Chang S.Y., Lee K-C., Ko S-Y., Ko H-J., Kang C-Y. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004, 111:86-95.
17. Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., Rosati M., Weiner D.B., Felber B.K., Pavlakis G.N., Sidhu M.K., Eldridge J.H., Egan M.A. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008, 26:4819-4829.
18. Gao N., Chen W., Zheng Q., Fan D-y, Zhang J-l, Chen H., Gao G.F., Zhou D-s, An J. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination. Immunol Lett 2010, 129:23-31.
19. Chen H., Gao N., Fan D., Wu J., Zhu J., Li J., Wang J., Chen Y., An J. Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice. PLoS One 2012, 7:e34602.
20. Loudon P.T., Yager E.J., Lynch D.T., Narendran A., Stagnar C., Franchini A.M., Fuller J.T., White P.A., Nyuandi J., Wiley C.A., Murphey-Corb M., Fuller D.H. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS ONE 2010, 5:e11021.
21. Bharati K., Appaiahgari M.B., Vrati S. Effect of cytokine-encoding plasmid delivery on immune response to Japanese encephalitis virus DNA vaccine in mice. Microbiol Immunol 2005, 49:349-353.
22. Yoon H.A., Aleyas A.G., George J.A., Park S.O., Han Y.W., Lee J.H., Cho J.G., Eo S.K. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol 2006, 50:83-92.
23. Zhang C., Wang B., Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease. Virol J 2011, 8:7.
24. Zheng Q., Fan D., Gao N., Chen H., Wang J., Ming Y., Li J., An J. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine 2011, 29:763-771.
25. Yang B., Lan X., Li X., Yina X., Baoyu Lia X.H., Li Y., Zhang Z., Liu J. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5' UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice. Vaccine 2008, 26:5477-5483.
26. Zhao H., Jiang T., Zhou X.Z., Deng Y.Q., Li X.F., Chen S.P., Zhu S.Y., Zhou X., Qin E.D., Qin C.F. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine. PLoS One 2014, 9:e86573.
27. Lin Y.L., Liu C.C., Lei H.Y., Yeh T.M., Lin Y.S., Chen R.M., Liu H.S. Infection of five human liver cell lines by dengue-2 virus. J Med Virol 2000, 60:425-431.
28. Marianneau P., Cardona A., Edelman L., Deubel V., Despres P. Dengue virus replication in human hepatoma cells activates NF-kappaβ which in turn induces apoptotic cell death. J Virol 1997, 71:3244-3249.
29. Mosier D.E. Human xenograft models for virus infection. Virology 2000, 271:215-219.
30. + T cells have both protective and pathogenic roles in dengue virus infection. Immunol Lett 2004, 95:167-174.
31. An J., Kimura-Kuroda J., Hirabayashi Y., Yasui K. Development of a novel mouse model for dengue virus infection. Virology 1999, 263:70-77.
32. Lu H., Xu X.F., Gao N., Fan D.Y., Wang J., An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. Mol Immunol 2013, 54:109-114.
33. Lee S.W., Cho J.H., Sung Y.C. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998, 72:8430-8436.
34. Kachko A., Kochneva G., Sivolobova G., Grazhdantseva A., Lupan T., Zubkova I., Wells F., Merchlinsky M., Williams O., Watanabe H., Ivanova A., Shvalov A., Loktev V., Netesov S., Major M.E. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. Vaccine 2011, 30:69-77.
35. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
36. Dorner M., Horwitz J.A., Donovan B.M., Labitt R.N., Budell W.C., Friling T., Vogt A., Catanese M.T., Satoh T., Kawai T., Akira S., Law M., Rice C.M., Ploss A. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013, 501:237-241.
37. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
38. Heystek H.C., Mudde G.C., Ohler R., Kalthoff F.S. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone. Clin Exp Immunol 2000, 120:440-447.
39. Zavala F., Abad S., Ezine S., Taupin V., Masson A., Bach J.F. G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol 2002, 168:2011-2019.
40. Mahnke K., Bedke T., Enk A.H. Regulatory conversation between antigen-presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007, 250:1-13.
41. Ganesh B.B., Cheatem D.M., Sheng J.R., Vasu C., Prabhakar B.S. GM-CSF-induced CD11c+CD8a dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol 2009, 21:269-282.
42. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004, 64:6337-6343.
43. Qin L., Greenland J.R., Moriya C., Cayabyab M.J., Letvin N.L. Effects of type I interferons on the adjuvant properties of plasmid granulocyte-macrophage colony-stimulating factor in vivo. J Virol 2007, 81:10606-10613.
44. Kusakabe K-i, Xin K.-Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., Okuda K., Miyagi Y., Aoki I., Nishioka K., Klinman D., Okuda K. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000, 164:3102-3111.
45. Zhao J., Lai L., Amara R.R., Montefiori D.C., Villinger F., Chennareddi L., Wyatt L.S., Moss B., Robinson H.L. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak post-challenge viremia. J Virol 2009, 83:4102-4111.
46. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1:376-382.
47. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18:226-232.
48. Mor G., Yamshchikov G., Sedegah M., Takeno M., Wang R., Houghten R.A., Hoffman S., Klinman D.M. Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest 1996, 98:2700-2705.
49. Gil L., Bernardo L., Pavon A., Izquierdo A., Valdes I., Lazo L., Marcos E., Romero Y., Guzman M.G., Guillen G., Hermida L. Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol 2012, 93:1204-1214.
50. Yu C.I., Chiang B.L. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010, 2010:548280.